This protocol covers functional dyspepsia (FD) in patients with confirmed Helicobacter pylori infection — a specific subpopulation for which a targeted, evidence-based management pathway applies.
The patient presents with functional dyspepsia and is positive for Helicobacter pylori infection. Evidence identifies H. pylori-positive patients with FD as candidates for a specific therapeutic intervention, separate from standard symptomatic management alone.
Management centres on an eradication-based approach directed at the underlying H. pylori infection. The complete protocol — including agent selection, sequencing, and clinical decision points — is available in the full structured regimen below.
The primary endpoint is cure of functional dyspepsia symptoms, assessed at 12 months.